Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) on Oct 20, 2025 launched the BD Incada™ Connected Care Platform, an AI-enabled, AWS-based cloud platform that unifies BD device data into a single ecosystem and supports analytics for nearly 3 million smart connected BD devices.

At the same time BD introduced the next-generation BD Pyxis™ Pro Dispensing Solution, a stackable automated medication dispenser that adds capacity (up to 538 multi-access or 98 secure pockets) in a similar footprint, and adds security, RFID badge scanning, wireless barcode scanning and illuminated bins.

The combined offering emphasizes enterprise-wide medication visibility, natural-language analytics, customizable dashboards, and secure cloud storage aimed at reducing medication waste, improving labor efficiency, and speeding point-of-care access. BD notes the Pyxis system processes about 9.8 million transactions per day.

BD (NYSE: BDX) celebrated 65 years of manufacturing at its Broken Bow, Nebraska facility on Oct. 16, 2025. The site opened Oct. 18, 1960 and has grown from a 13,753-square-foot plant with 20 associates to a 310,000-square-foot facility employing nearly 600 associates.

Broken Bow is described as the world's largest manufacturer of BD Vacutainer® tubes, producing billions of tubes and other collection products annually. BD reports more than $50 million invested in Nebraska since 2020 and announced a separate >$35 million investment and 50 jobs at its Columbus facility. BD operates 30+ U.S. sites with ~10,000 employees.

BD (NYSE: BDX) announced a CFO transition: Chris DelOrefice will depart effective Dec. 5, 2025 and Vitor Roque will become interim CFO. The company provided preliminary unaudited results for the period ended Sept. 30, 2025, including Q4 revenue ≈ $5.9 billion (reported +8.3%, currency‑neutral +7.0%, organic +3.9%) and full‑year revenue ≈ $21.8 billion (reported +8.2%, currency‑neutral +7.7%, organic +2.9%).

BD expects fiscal 2025 adjusted diluted EPS to be at or above the midpoint of prior guidance, and will discuss results on an audio webcast Nov. 6, 2025. Preliminary figures are unaudited and subject to change.

BD (NYSE: BDX) said management will host an audio webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to discuss fourth-quarter and full-year fiscal 2025 results (fiscal year ended September 30, 2025) and provide an operations and strategy update.

The company will issue a news release and presentation materials with summary financial information prior to the call. The live webcast and a replay will be available at www.bd.com/investors.

BD (NYSE: BDX) announced enrollment of the first patient in the XTRACT™ Registry on September 29, 2025, a prospective, multi-center, single-arm post-market study to evaluate real-world performance of the Rotarex™ Catheter System for peripheral artery disease (PAD).

The registry plans up to 600 patients across as many as 100 U.S. sites with follow-ups at 30 days, 6 months, and 12 months to assess safety and effectiveness. The Rotarex catheter offers combined atherectomy and thrombectomy mechanisms to remove plaque and thrombus. BD said the registry will generate real-world evidence to inform clinical decision-making and treatment strategies for PAD.

BD (NYSE: BDX) and Opentrons announced a multi-year collaboration on Oct 8, 2025 to integrate Opentrons robotic liquid-handling into BD single-cell multiomics instruments.

The partnership intends to integrate the BD Rhapsody System with the Opentrons Flex platform, develop verified protocols, and build an automation-compatible module to automate next-generation sequencing library preparation and cell capture, enabling hands-free workflows and scaling to million-cell studies.

Early access opportunities will be available and both companies will present details at the ASHG Annual Meeting, Oct 14–18, 2025 (BD Booth 447; Opentrons Booth 635).

BD (NYSE: BDX) celebrates 55 years of manufacturing at its Sumter, South Carolina facility on Oct. 3, 2025. The site began in 1970 with 25 employees and now spans >600,000 square feet, employs ~900 associates and produces billions of products annually, including BD Vacutainer® blood collection products that the company says care for 84 patients every second.

Since FY21, BD invested more than $90 million in Sumter, tripled year-over-year investment from FY24 to FY25, and plans to invest ~$30 million in FY26 for modernization, new lines and training. BD announced a $10,000 donation to the Tuomey Foundation and contributes >$100,000 annually to local organizations. BD operates >30 U.S. manufacturing and distribution sites across 17 states and Puerto Rico, employing >10,000 people.

BD (NYSE: BDX) has announced a groundbreaking pharmacy automation partnership with Henry Ford Health to revolutionize medication storage and prescription delivery. The collaboration centers on implementing the BD Rowa™ Vmax, a sophisticated pharmacy automation robot, across Henry Ford Health's hospital-based community pharmacies in Southeast and Central Michigan.

The partnership will enable 24/7 prescription access for patients and features automated high-capacity storage for safe and accurate prescription retrieval. This innovative system, already widely used in Europe, will allow pharmacy staff to focus on higher-value patient care tasks while improving operational efficiency. The implementation includes capabilities for real-time prescription tracking and can accommodate refrigerated medications, supplies, and over-the-counter products.

BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.

The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.